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Abstract
Background: Health professionals and organizations in developed countries adapt slowly to the increase of ethnically 
diverse populations attending health care centres. Several studies report that attention to immigrant mental health 
comes up with barriers in access, diagnosis and therapeutics, threatening equity. This study analyzes differences in 
exposure to antidepressant drugs between the immigrant and the native population of a Spanish health region.
Methods: Cross-sectional study of the dispensation of antidepressant drugs to the population aged 15 years or older 
attending the public primary health centres of a health region, 232,717 autochthonous and 33,361 immigrants, during 
2008. Data were obtained from computerized medical records and pharmaceutical records of medications dispensed 
in pharmacies. Age, sex, country of origin, visits, date of entry in the regional health system, generic drugs and active 
ingredients were considered. Statistical analysis expressed the percentage of persons exposed to antidepressants 
stratified by age, gender, and country of origin and prevalence ratios of antidepressant exposition were calculated.
Results: Antidepressants were dispensed to 11% of native population and 2.6% of immigrants. Depending on age, 
native women were prescribed antidepressants between 1.9 and 2.7 times more than immigrant women, and native 
men 2.5 and 3.1 times more than their immigrant counterparts. Among immigrant females, the highest rate was found 
in the Latin Americans (6.6%) and the lowest in the sub-Saharans (1.4%). Among males, the highest use was also found 
in the Latin Americans (1.6%) and the lowest in the sub-Saharans (0.7%). The percentage of immigrants prescribed 
antidepressants increased significantly in relation to the number of years registered with the local health system. 
Significant differences were found for the new antidepressants, prescribed 8% more in the native population than in 
immigrants, both in men and in women.
Conclusions: All the immigrants, regardless of the country of origin, had lower antidepressant consumption than the 
native population of the same age and sex. Latin American women presented the highest levels of consumption, and 
the sub-Saharan men the lowest. The prescription profiles also differed, since immigrants consumed more generics 
and fewer recently commercialized active ingredients.
Background
The health of immigrant populations is an issue that has
aroused a great deal of interest in recent years. The huge
increase in the numbers of ethnically and culturally dif-
ferent populations attending health centres in our geo-
graphical setting obliges health professionals and
organizations to adapt to this new situation and to
respond to the needs of these new users. In general, this
process of adaptation is slow.
The psycho-social process of loss and change that
immigrants experience has been likened to a process of
mourning [1]. It may develop favourably, or it may deteri-
orate into a pathological process associated with chronic
and multiple stress (Ulysses' Syndrome). This means that
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Page 2 of 12the mental health of immigrants is a priority research
issue. Immigrants cannot be considered as a homoge-
neous group as regards the risk of mental illness, and
indeed many studies suggest that this risk is not systemat-
ically present in all immigrant groups; however, in spe-
cific circumstances certain factors may favour the
development of mental illness and may increase the likeli-
hood that immigrants will seek help at health centres [2].
Studies of the prevalence of mental illness in immi-
grants come up against a series of obstacles that make the
identification and diagnosis of this pathology particularly
difficult. These include the understandable fear of detec-
tion felt by illegal immigrants, their lack of information
regarding access to the health system, and their inability
to communicate freely due to linguistic difficulties. To
compound the problem, the registration systems in use
are not designed for a situation of large-scale immigra-
tion; the health staff may know little of the immigrants'
cultures, and the traditional psychometric scales used to
diagnose psychiatric illness may have little transcultural
validity [3-5]. Finally, the cultural background of each
ethnic group is deeply involved in the mental health con-
cept, identification and help seeking attitudes, resulting
in a great variability of situations. For all these reasons,
the reports of the prevalence of mental disorder in this
group may be unreliable.
In Spain, where the percentage of economic immigra-
tion is high, several studies have investigated mental
health in the immigrant population. Pertíñez et al. found
no significant differences in the percentages of mental ill-
ness in a sample of 112 immigrants and 112 natives seen
at a health centre between 1995 and 1997, although 32%
of the native-born patients were receiving psychodrugs,
compared with 20% of the immigrants [6]; Pardo et al.
concluded that the prevalence of depression in a sample
of 606 sub-Saharan immigrants was similar to that in the
native population, although only 6% of immigrant
patients diagnosed with depression received antidepres-
sant treatment [7]. In contrast, Barro et al. found higher
prevalence of anxiety and depression in a sample of 27
illegal immigrants in the same region in 2003 [8].
Analysing the most frequent diagnoses for which legal
immigrants were attended in psychiatric units, Ochoa et
al. found them to be similar to those recorded in native
patients: anxiety, adaptive disorders, and depression [9].
In a study conducted in a Spanish health region in 2005,
Rué et al focused on differences in the general consump-
tion of drugs between a broad sample of immigrants and
native patients. They found lower expenditure in the
immigrant sample, a lower percentage of prescriptions
dispensed, fewer packages withdrawn and lower prices
[10]. These findings support the hypothesis that active
ingredients may be prescribed differently in the two
groups because newer drugs are often more expensive
and therefore generic medications would be more fre-
quently prescribed to immigrants because of their lower
cost.
In the light of these findings, we designed the present
study to compare the percentages of antidepressant use in
the immigrant and native populations in a Spanish health
region over a period of a year. As the immigrant sample
was large, we also divided them into subgroups according
to their area of origin. Finally, we also analysed whether
the profile of antidepressant prescription differed
between the native and immigrant populations in terms
of active ingredients (AI) and the use of generic drugs.
Methods
Type of study and setting: Cross-sectional, descriptive
study of the dispensation of antidepressant drugs (AD)
during the 2008 calendar year in a Spanish health region
(HR).
Study population
Population aged 15 years or older assigned to any of the
Catalan Health Institute's 21 centres in the health region
of Lleida, who were recorded in the Insured Persons Reg-
istry (IPR) during the 2008 calendar year. The IPR identi-
fies each insuree using a personal identification code. At
the time of the study, 95% of the population on the census
roll in the HR were listed in the IPR, received health care
and were entitled to drug prescription. In the Spanish
public health system, drugs are prescribed free to those
over the age of 65 and at a 60% discount to patients under
this age. An official prescription is needed to obtain AD
drugs. The Health Region's economy is based on agricul-
ture and livestock farming, with the result that immigra-
tion is eminently labour-oriented. The proportion of the
foreign population has risen from 2.6% in 2000 to 14.1%
in 2007 [11]. To assess the representativeness of our sam-
ple, the distribution by countries of origin of the popula-
tion assigned to the health centres was compared with
that of the population recorded on the census in the HR.
Variables
The demographic variables considered were age, sex and
country of origin. The administrative variables analysed
were the date of entry in the region's health system, con-
tact with the health centre and the number of visits made
during the year of the study. As regards AD consumption,
the prescription of generic or brand drugs and the active
ingredient were recorded, according to the N06A thera-
peutic subgroup of the Anatomical Therapeutical Chemi-
cal (ATC) Classification System [12].
Classification of the population as immigrant/native:
individuals born in Spain were considered as natives, and
those from countries with medium or low income
according to the World Bank web page [13] were consid-
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unknown, subjects were considered to be natives if they
were listed in the IPR prior to 1 January 2003, when the
percentage of immigrants in the HR was below 5%.
Subclassification of the immigrants according to area of
origin: Foreign subjects were classified into five culturally
different groups: Eastern European, Maghribi, Latin
American, Sub-saharan African and Other.
Exclusions
Service users who moved to other areas or who died in
2008 were excluded, as were those whose identification
codes were provisional or incomplete, and foreigners
from high income countries. The selection process is
shown in figure 1.
Sources of data
Demographic, administrative and clinical data of the
study population were obtained from the clinical histo-
ries stored electronically in the Primary Care Information
System. The population of the HR was obtained from the
December 2008 municipal census. The information on
patients' drug use was obtained from the prescriptions
dispensed at the pharmacy offices, as official prescription
is obligatory for medication of this kind. This information
was provided by the HR Pharmacy Unit of the Catalan
Health Service and was compared with the administrative
and clinical data using a common identification code.
Permission to use this data was obtained from authorized
personnel in the Catalan Health Service and the Direc-
tory of Primary Care. All data were treated anonymously
to ensure confidentiality. Being an observational retro-
spective study, no ethical approval was considered neces-
sary.
Analysis
A descriptive statistical analysis was performed express-
ing the number and the percentage of users prescribed
AD, stratified by levels of the qualitative variables (age
group, sex, population and area of origin). The 95% confi-
dence interval (95%) of the rates of prescription and prev-
alence ratios was calculated using the normal
approximation. To evaluate the association between AD
prescription and population group we estimated the
prevalence ratio of AD use in the native and immigrant
populations together with the 95% CI. To evaluate the
relationship between AD prescription and the time regis-
tered with the health system, the linear trend test of the
X2 was used.
We analysed the active ingredient and the use of
generic or brand drugs for the subgroup of patients pre-
scribed AD, calculating the percentages stratified by pop-
ulation and sex. The percentages were compared with the
X2 test.
Results
1. Description of the study population
1.1. Origin, age and sex
The study population comprised 266,078 individuals.
Immigrants from low or medium income countries -
Eastern Europe, the Maghrib, Latin America and sub-
Saharan Africa - accounted for 12.5%.
The immigrant population was younger (median age 34
years, SD = 10 years) than the native population (median
age 49 years, SD = 20 years). The distributions according
to area of origin, age group and sex are shown in table 1.
The percentage of women varied according to origin,
from 58% among the Latin Americans to 20% in the sub-
Saharans. Immigrants aged over 65 years accounted for
only 1.1% of the total.
1.2. Contact with the health system
In all, 90% of the Latin Americans, 84% of the sub-Saha-
rans, 81% of the Maghribis and 70% of the Eastern Euro-
peans on the census roll in the HR were assigned to
health centres. The comparison of the distribution of the
main cultural groups in both registries was as follows
(census versus IPR, in percentages): native, 81.4 vs. 84.9;
Latin America, 3.1 vs. 2.9; Eastern Europe, 7.1 vs.5.2;
Maghreb, 4.5 vs. 3.8; Sub-Saharan Africa, 2.7 vs. 2.4.
In 2008, 69.7% of the immigrant population studied
were attended at primary care centres, compared with
81.6% of the native population. The median annual num-
ber of visits was 6 in the immigrant group and 9 in the
natives.
Focusing on our subsamples, 74.3% of the Maghribis
were attended at primary care centres, 73% of the Latin
Americans, 69.6% of the sub-Saharans and 63.2% of the
Eastern Europeans. The median annual number of visits
was 6 in the first three groups and 5 in the Eastern Euro-
peans.
According to the IPR data, the Maghribi group were the
longest established; 20% of its members had spent more
than seven years in the HR. The most recent arrivals were
the Eastern Europeans, 45.7% of whom had registered in
the last two years.
2. AD prescription
Ten per cent of the study population (26,513 subjects)
withdrew at least one AD from the pharmacy in 2008:
11% of the native population and 2.6% of the immigrant
population.
AD use was higher in the native population than in the
immigrants in both sexes and in all age groups. Depend-
ing on age, native women were prescribed AD between
1.9 and 2.7 times more frequently than immigrant
women, and native men 2.5 and 3.1 times more than their
immigrant counterparts (table 2).
AD consumption differed in our immigrant subsam-
ples. Among females, the highest rate was found in the
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Figure 1 Selection process of the study population.
380,831 individuals assigned
 6365 excluded for having only a provisional health card
49,640 excluded due to age (under 15)
23,185 excluded due to transfer to another HR in 2008
13,702 excluded due to death in 2008
9,083 excluded due to unknown country of origin and 
entry after 31/12/2002
797 excluded due to high income country of origin
361 excluded due to coding errors 
10,605 excluded for registering with the IPR in 2008
266,078    study individuals 
Native
232,717 
Immigrant 
33,361
Latin America               6,641 
Eastern Europe          12,077
Maghrib                        8,346
Sub-Saharan Africa    5,412 
Other nationalities           885 
Cruz et al. BMC Public Health 2010, 10:255
http://www.biomedcentral.com/1471-2458/10/255
Page 5 of 12Table 1: Distribution of the population according to area of origin, age group and sex.
Latin America Eastern Europe Maghrib Sub-Saharan 
Africa
Other Native
n % n % n % n % n % n %
WOMEN 15-24 
years
646 16.8 1341 21.4 655 23.8 191 17.6 75 21.4 12496 10.6
25-34 
years
1422 36.9 2509 40.1 1072 39.0 602 55.5 117 33.3 17825 15.1
35-44 
years
1058 27.5 1526 24.4 637 23.2 222 20.5 114 32.5 19816 16.8
45-54 
years
475 12.3 625 10.0 246 9.0 53 4.9 30 8.5 18630 15.8
55-64 
years
144 3.7 193 3.1 84 3. 10 0.9 8 2.3 15885 13.4
> = 65 
years
107 2.8 58 0.9 53 1.9 6 0.5 7 2.0 33453 28.3
MEN 15-24 
years
585 21.0 1004 17.2 678 12.1 459 10.6 85 15.9 13377 11.7
25-34 
years
918 32.9 2218 38.1 2253 40.2 2145 49.6 198 37.1 19170 16.7
35-44 
years
801 28.7 1651 28.3 1842 32.9 1355 31.3 188 35.2 21224 18.5
45-54 
years
347 12.4 764 13.1 636 11.4 318 7.3 53 9.9 19716 17.2
55-64 
years
95 3.4 163 2.8 128 2.3 47 1.1 6 1.1 15472 13.5
> = 65 
years
43 1.5 25 0.4 62 1.1 4 0.1 4 0.7 25653 22.4
Total Men 2789 42 5825 48.2 5599 67.1 4328 80 534 57 114612 49.2
Total Women 3852 58 6252 51.8 2747 42.9 1084 20 351 43 118105 50.8
TOTAL by area 6641 20 12077 36.2 8346 25 5412 16.2 885 2.6 232717
Latin Americans (6.6%) and the lowest in the sub-Saha-
rans (1.4%). Similarly, among the males, the highest AD
use was also found in the Latin Americans (1.6%) and the
lowest in the sub-Saharans (0.7%) (Table 3).
The percentage of immigrants prescribed AD also
increased significantly (p < 0.001) in relation to the num-
ber of years registered with the local health system. This
was the case in all age groups: when time on IPR was 1-2
years, the percentage of AD use increased from 0. 96 in
the youngest to 3.33 in the 55 to 64 years old; in the other
end, when the time on IPR was 9 years or more, the per-
centages for the same age groups were 2.16 and 8.97
respectively.
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3.1. Generics
Overall, 32.2% of users prescribed AD received generics:
33.4% of women and 29.2% of men (p < 0.001), and 44.2%
of immigrants compared with 31.8% of natives. The RR of
receiving generics among the immigrants was 1.4 (95%CI
1.29 - 1.5).
The use of generics also varied depending on the area
of origin: 47.5% in Latin Americans (95%CI 46.3-48.7),
45.1% in Eastern Europeans (95%CI 44.2-46.0), 42.3% in
Maghribis (95%CI 41.2-43.4) and 28.9% in sub-Saharan
Africans (95%CI 27.7-30.1).
3.2. Active ingredients
Types of drug dispensed are shown in table 4, presented
according to group and sex.
The most frequently prescribed subgroup (above 72%
in both populations) were selective serotonin reuptake
inhibitors (paroxetine, escitalopram, citalopram and flu-
oxetine), followed by tricyclic antidepressants (amitrip-
tyline and clomipramine, between 17% and 21%, with
higher percentages of the former in immigrants). Clini-
cally significant differences were found for serotonin-
norepinephrine reuptake inhibitors (duloxetine and ven-
lafaxine), noradrenaline and dopamine reuptake inhibi-
tors (bupropion and reboxetine) and specific
noradrenergic and serotoninergic antidepressants (mir-
tazapine and oxitriptan), which were prescribed 8% more
in the native population than in immigrants, both in men
and in women.
The rates of prescription of the various AI differed in
our subsamples, with the greatest differences for amitrip-
tyline, especially in the Maghribi and sub-Saharan groups
(see table 5).
Discussion
Antidepressant consumption in the immigrant popula-
tion registered at the health centres in this Health Region
was between 40% and 75% lower than in the native popu-
lation of the same age and sex (prevalence ratio of native
vs. immigrants between 1.64 and 4.1).
Comparison with other countries
This finding corroborates the differences already
reported in countries which traditionally have high rates
of immigration. A recent systematic review by Uiters et
al. underlined the importance of the effect of the host
country and its health system on the use of services by the
immigrant population. Those authors found more differ-
ences in countries with weaker primary care systems such
as the US than in areas with stronger primary health care
such as Canada and Europe [14].
In the United States, various studies in broad samples
coincide in demonstrating that access to AD is especially
limited in Afroamericans [15-17]. Williams et al. analysed
data from national mental health surveys for Black Afri-
cans, White Americans and Black Caribbeans; although
the lifetime prevalence of depression was lower in the
Black population, the disorder was more persistent and
Table 2: Percentage of exposure and risk ratio of AD use in native subjects versus immigrants, by sex and age group
Immigrants Native Prevalence ratio
% % 95%CI
WOMEN 15-24 years 1.86 3.55 1.91 (1.45 2.53)
25-34 years 3.98 6.52 1.64 (1.43 1.88)
35-44 years 5.65 10.61 1.88 (1.63 2.16)
45-54 years 6.30 15.89 2.52 (2.06 3.09)
55-64 years 7.29 21.14 2.90 (2.07 4.05)
> = 65 years 9.09 24.23 2.67 (1.77 4.01)
MEN 15-24 years 0.68 1.72 2.54 (1.60 4.05)
25-34 years 1.03 3.73 3.60 (2.87 4.54)
35-44 years 1.54 5.24 3.40 (2.75 4.21)
45-54 years 1.56 6.44 4.13 (2.93 5.82)
55-64 years 2.05 8.18 3.99 (2.09 7.64)
> = 65 years 3.62 11.40 3.15 (1.33 7.44)
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treatment [17].
In Europe the prevalence of mental illness has been
examined in ethnic minorities, and although less research
has been conducted of their pharmacological treatment
some studies suggest the existence of differences. One
study in the UK, for example, found that Asians received
fewer AD and anxiolytics than the rest of the population
[18].
As we noted above, studies of mental illness in immi-
grants have been carried out in Spain, but few compare
the rates of pharmacological treatment received by immi-
grants and natives. Most of those conducted to date are
based on interviews of small samples, selected using dif-
ferent criteria which do not allow analysis of the differ-
ences between subgroups from different cultures.
Discussing factors related to the results
In the analysis we included a variety of factors that may
have a bearing on the lower use of AD in the immigrant
group.
The first point to consider is whether the prevalence of
depression is the same across the populations. It has been
suggested that there are substantial differences across
Table 3: Percentage of patients consuming AD according to origin, sex and age group.
Latin America Eastern Europe Maghrib Sub-Saharan Africa Native
n % n % n % n % n %
WOMEN 15-24 
years
646 3.6 1341 1.5 655 1.7 191 0 12496 3.5
25-34 
years
1422 5.3 2509 4.6 1072 2.8 602 0.8 17825 6.5
35-44 
years
1058 7.7 1526 4.6 637 6.3 222 3.1 19816 10.6
45-54 
years
475 10.1 625 4.3 246 4.5 53 3.8 18630 15.9
55-64 
years
144 11.8 193 4.1 84 8.3 10 0 15885 21.1
> = 65 
years
107 10.3 58 6.9 53 1.9 6 16.7 33453 24.2
Total 
Women
3852 6.6 6252 3.9 2747 3.6 1084 1.4 118105 15.3
MEN 15-24 
years
585 1.0 1004 0.7 678 0.7 459 0 13377 1.7
25-34 
years
918 1.3 2218 1.2 2253 1.0 2145 0.8 19170 3.7
35-44 
years
801 2.5 1651 1.7 1842 1.7 1355 0.6 21224 5.2
45-54 
years
347 2.0 764 0.8 636 2.7 318 0.9 19716 6.4
55-64 
years
95 1.0 163 1.8 128 3.1 47 2.1 15472 8.2
> = 65 
years
43 0 25 8 62 3.2 4 25 25653 11.4
Total 
Men
2789 1.6 5825 1.2 5599 1.5 4328 0.7 114612 6.6
TOTAL 
area
6641 4.5 12077 2.6 8346 2.2 5412 0.8 25651 11.0
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Page 8 of 12ethnic subgroups. Unfortunately, the data available from
different countries in the world are difficult to compare
due to the differences in the diagnostic criteria and
instruments applied and in the demographic characteris-
tics of the samples studied. In Spain, the most recent
information, from the ESEMeD project (2009), reported a
prevalence of major depressive episode above 4% in the
last year or 10.6% during the lifetime, rates lower than
those found in the other western countries that took part
in the project [19]. In Latin America, using similar crite-
ria, yearly prevalence of 4.9% [20] and lifetime prevalence
of 9.2% [21] has been reported. In Africa, studies with
similar methodologies have also obtained variable yearly
prevalence: Nigeria 1.1% [22], Ethiopia 4.4% [23], South
Africa 4.9% [24]. Studies in Eastern European countries
using different instruments have obtained higher preva-
lence, ranging from 21% in Poland and 33% in Russia [25].
Finally, there are few data from North African countries,
but a study of the prevalence of anxiety and depression in
immigrants living in the Netherlands found figures of
10% in Moroccans (and 19% in Turks) compared with
6.6% in the native Dutch population [26]. With occasional
exceptions, then, the prevalence of depression in immi-
grants from these areas is not lower than that found in
the Spanish population and does not explain the large dif-
ference in treatment, although inter-ethnic differences
should be taken into account.
Secondly, the lack of objective data on the prevalence of
depression in our immigrant sample means that we can-
not evaluate the hypothesis of undertreatment because of
underdiagnosis. This hypothesis has been suggested by
multiple studies: in the US, for example, Borowsky et al.
found that primary care physicians were less likely to
detect mental health problems among African Americans
and Hispanics than among White Americans [27]. Later
studies obtained similar rates of prescription of AD treat-
ment for the three groups, but reported a much lower
likelihood that Africans and Hispanics would take the
medication than Whites [28]. Although the latter result
suggests that GPs are now more alert to the problem and
are better at diagnosing depression in countries where
the subject has been researched for many years, it does
not explain why the differences in AD consumption per-
sist.
Treating patients from other cultures remains a signifi-
cant problem for primary care physicians in most coun-
tries. The obstacles they face include the inadequacy of
the diagnostic tools and clinical guides at their disposal
and the difficulty of distinguishing between the symp-
toms caused by traumatic experiences and adverse life
conditions and those caused by depression. They may
also need to overcome gender stereotypes in mental ill-
ness to avoid under- or over-estimation of depressive
symptoms [29].
The third factor to consider is the low level of contact
with health system [30]. The lower the contact, the lower
the levels of diagnosis and treatment. Indeed, in our
study, the percentage of immigrants visiting the doctor at
the health centres was lower than that of the native popu-
lation (68.7% vs. 81.6%). These data corroborate the find-
ings of previous studies (e.g. Saura et al., [5]), and have
been attributed to the lack of information regarding the
health system and of the possibilities of access for those
who are not legally resident [3]. In our study, however, all
Table 4: Number and percentage of patients exposed to different treatments, according to origin and sex.
Immigrants Native
Men Women Men Women
n = 236 n = 626 n = 7517 n = 18134
n % n % n % n %
N06AA ADT/HETEROC.(1) 49 20.8 129 20.6 1297 17.2 3341 18.4
N06AB SSRI(2) 170 72.0 484 77.3 5515 73.4 13629 75.2
N06AG MAOI(3) 0 0 0 0 0 0 1 0.0
N06AX SNRI/NDRI/
SP.NORADREN. SEROT.(4)
35 14.8 91 14.5 1776 23.6 4105 22.6
(1) Tricyclic and heterocyclic antidepressants
(2) Selective serotonin reuptake inhibitors
(3) Monoaminooxidase inhibitors
(4) Serotonin-norepinephrine reuptake inhibitors/noradrenaline and dopamine reuptake inhibitors/specific noradrenergic and 
serotoninergic antidepressants
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Page 9 of 12the population included were legally entitled to health
care, and had been registered with their health centre for
at least one year; therefore, the obstacles would not be to
do with the subjects' legal status but with other no less
important causes such as linguistic difficulties, cultural
differences in the perception of the need to seek medical
advice, or the search for alternative solutions to health
problems.
Another parameter to take into account in relation to
depression is the time already spent in the country. The
illness usually emerges as time passes and as immigrants
begin to feel that their expectations have not been ful-
filled [31]. As we had no precise information on this issue
we used an indirect indicator - the date of entry to the
health system in the region - as a measure of time flows,
of the stability of subjects' residence in the region, and of
their adaptation to the local environment over time. Most
of the immigrants had arrived in the last four years: the
Maghribis and Latin Americans were the most stable
groups, although the low numbers of individuals with
more than five years' residence means that the results for
longer periods should be interpreted with caution. In all
age groups, AD consumption increased with time regis-
tered in the IPR, supporting the hypothetical model of
the healthy immigrant whose health deteriorates with the
passing of time. Furthermore, the groups with the highest
rates of AD use, the Latin Americans and Eastern Euro-
peans, were not the ones who had spent the longest in the
region, a finding that suggests the influence of other fac-
tors related to the culture of origin.
Finally, we should stress that the decision to withdraw
medication from the pharmacy is taken by the patient. A
GP or psychiatrist may prescribe a drug, but the patient's
intention to take it may be influenced by a range of cir-
cumstances. For instance, immigrant populations gener-
ally have low economic resources and the obligation of
paying 40% of the price of the drug may be a deterrent.
The acceptance of the diagnosis and the pharmacological
treatment may also influence the decision to take the
medication; in a study in the US, Cooper et al. observed a
lower likelihood to accept AD medication in African
Americans and Hispanics and a higher prevalence of neg-
ative beliefs [32].
Differences across ethnic groups
The group with the highest AD consumption was the
Latin American group, especially the women, and the one
with the lowest was the sub-Saharan group, although the
samples are too small to be able to generalize the results.
Possibly these findings reflect the fact that the cultural
and linguistic differences vis-à-vis the study setting are
far greater in the case of the sub-Saharans than in the case
of the Latin Americans.
In the case of the sub-Saharans, the concept of depres-
sion has changed radically in recent times. Historically
non-existent or extremely rare, the prevalence of depres-
sion in these countries is now equal to or higher than
those reported in the developed world, even among dif-
ferent ethnic groups. Recent studies of attitudes to mental
illness in low-income communities in South Africa report
stigmatization of mental patients, ignorance of the
causes, and little effort to seek treatment [33]. A broad
survey carried out in 2007 in the US found that ethnic
minorities were less likely to believe in the effectiveness
of medication or in the biological basis of depression, and
more likely to believe in the effectiveness of advice and
prayer [34]. Clearly, there is a need for further studies of
attitudes to mental illness in these groups.
Table 5: Main active ingredients dispensed according to area of origin (numbers and percentages).
NATIVE IMMIGRANTS Latin America Eastern Europe Maghrib Sub-Saharan 
Africa
n % n % n % n % n % n %
Paroxetine 5793 22.6 260 30.2 85 28.2 113 35.6 44 24.2 11 24.4
Escitalopram 5280 20.6 144 16.7 47 15.6 63 19.9 28 15.4 5 11.1
Citalopram 3913 15.3 146 16.9 60 19.9 53 16.7 29 15.9 4 8.9
Fluoxetine 3226 12.6 98 11.4 46 15.3 30 9.5 18 9.9 2 4.4
Venlafaxine 2899 11.3 52 6.0 21 7.0 17 5.4 13 7.1 1 2.2
Sertraline 2452 9.6 59 6.8 23 7.6 21 6.6 9 4.9 4 8.9
Duloxetine 2067 8.1 45 5.2 15 5.0 18 5.7 10 5.5 1 2.2
Amitriptyline 1897 7.4 122 14.2 38 12.6 27 8.5 41 22.5 13 28.9
Clomipramine 1442 5.6 32 3.7 10 3.3 7 2.2 14 7.7 1 2.2
Mirtazapine 1342 5.2 38 4.4 14 4.7 10 3.2 10 5.5 4 8.9
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As regards type of drug, immigrants were prescribed
higher levels of generics and lower levels of recently com-
mercialized drugs such as venlafaxine or duloxetine.
These results can be attributed to an attempt on the part
of physicians to reduce the cost of the medication in
patients assumed to have low or zero purchasing power
and thus to increase the likelihood of compliance with
treatment. We intend to explore this idea further using a
cost analysis per patient in a future study.
Strengths and limitations
One of the strong points of the present study is its large
population-based sample and its comparison of the
results of immigrants and the native population, with
data from 232,717 Spanish nationals, 12077 Eastern
Europeans, 8346 Maghribis, 6641 Latin Americans, 5412
sub-Saharans and 885 individuals of other nationalities.
As the proportions according to area of origin and sex of
the sample matched those published by the Catalan Sta-
tistics Institute for the same year, 2008 [11], we believe
that our data are representative of the populations of ori-
gin, even though the study was performed in a specific
geographical area.
The main limitations of the study are due to the selec-
tion of the sample. First, immigrants who were not legally
registered in Spain were not included, since they do not
have an identity card or health or pharmaceutical cover-
age. For this reason, the results can only be extrapolated
to immigrants who are legally registered. Second, to
establish whether the immigrant population assigned to
health centres was representative of the immigrants in
the health region as a whole we compared their distribu-
tion with the data from the municipal census. We found
that the Latin Americans, Maghribis and sub-Saharans
registered at the health centres accounted for between
80% and 90% of those registered on the census, but in the
case of the Eastern Europeans the figure fell to 70%. We
cannot rule out the possibility of a selection bias, espe-
cially in the latter group, as we do not know whether the
population that has not contacted the health system dif-
fers in terms of mental health from the population stud-
ied. Third, we also decided to exclude patients who
registered for the first time, moved, or died during the
calendar year studied in order to make sure that the
observation period was the same for all subjects. Fourth,
as regards the country of origin, our decision to classify as
native all subjects who did not report their country of ori-
gin and who had been living in the study area at the end
of 2002, when the proportion of immigrants was under
5%, may have introduced a bias. Equally, in grouping the
patients into four areas of origin to increase the power of
the analysis we used our own subjective criteria of ethnic/
cultural similarity, which are obviously debatable.
We stress that AD prescription does not necessary
imply the diagnosis of a depressive disorder, since these
drugs may also be prescribed for other health problems
[35]; however, this limitation would be expected to affect
all the population equally, regardless of their country of
origin. Nor does the act of obtaining medication from the
pharmacy guarantee compliance with treatment. Estab-
lishing the prevalence of depressive disorder in the two
groups and assessing compliance with treatment are
beyond the scope of this analysis, but there is no doubt
that this information would be useful for evaluating the
conclusions, and so attempts should be made to deter-
mine these variables in future studies.
We are also aware of the possibility of obtaining AD
from other sources, but this appears difficult because, in
Spain, AD can only be dispensed with a medical prescrip-
tion and thus would be registered in the database. As far
as we know, there are no other organizations in the HR
that can provide this service.
Finally, the analysis of AD consumption was performed
using an electronic database of prescriptions. Databases
of this kind have demonstrated their usefulness for epide-
miological analysis of medication consumption patterns
in various clinical entities [36-42] carried out from a pop-
ulation perspective.
Conclusions
All the immigrants, regardless of the country of origin,
had lower AD consumption than the native population of
the same age and sex.
For all the immigrant population, AD consumption
tended to increase with time spent in the health region,
reflecting either a deterioration of their health or
improved access to the health system.
Latin American women presented the highest levels of
AD consumption, and the sub-Saharan men the lowest.
The prescription profiles also differed, since immi-
grants consumed more generics and fewer recently com-
mercialized active ingredients. This suggests a strategy of
cost reduction in order to improve accessibility to medi-
cation.
The rather limited bibliography available on the preva-
lence of depression in immigrants does not explain the
clearly lower rates of treatment found in this population.
Further studies in specific social and health settings are
required to identify and understand the causes of the dif-
ferences found here between our ethnic subsamples.
These studies should focus on specific groups, especially
the sub-Saharans, and determine whether immigrants
and natives with the same levels of need enjoy the same
access to medication and care.
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